CN112675226A - Fumigation-washing traditional Chinese medicine composition for treating pain and application thereof - Google Patents
Fumigation-washing traditional Chinese medicine composition for treating pain and application thereof Download PDFInfo
- Publication number
- CN112675226A CN112675226A CN202110162397.4A CN202110162397A CN112675226A CN 112675226 A CN112675226 A CN 112675226A CN 202110162397 A CN202110162397 A CN 202110162397A CN 112675226 A CN112675226 A CN 112675226A
- Authority
- CN
- China
- Prior art keywords
- parts
- root
- traditional chinese
- angelica
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 84
- 239000000203 mixture Substances 0.000 title claims abstract description 70
- 208000002193 Pain Diseases 0.000 title claims abstract description 37
- 230000036407 pain Effects 0.000 title claims abstract description 37
- 238000005406 washing Methods 0.000 title claims abstract description 7
- 241000213006 Angelica dahurica Species 0.000 claims abstract description 28
- 239000002994 raw material Substances 0.000 claims abstract description 27
- 241000195954 Lycopodium clavatum Species 0.000 claims abstract description 24
- 240000007311 Commiphora myrrha Species 0.000 claims abstract description 23
- 235000006965 Commiphora myrrha Nutrition 0.000 claims abstract description 23
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 23
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 23
- 235000007265 Myrrhis odorata Nutrition 0.000 claims abstract description 23
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 23
- 229940079593 drug Drugs 0.000 claims abstract description 23
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 22
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 22
- 244000018716 Impatiens biflora Species 0.000 claims abstract description 21
- 235000015912 Impatiens biflora Nutrition 0.000 claims abstract description 21
- 235000005155 Tanacetum balsamita Nutrition 0.000 claims abstract description 21
- 241001254604 Angelica pubescens Species 0.000 claims abstract description 20
- 241000218158 Clematis Species 0.000 claims abstract description 20
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 20
- 235000011477 liquorice Nutrition 0.000 claims abstract description 20
- 231100000862 numbness Toxicity 0.000 claims abstract description 17
- 241000427159 Achyranthes Species 0.000 claims abstract description 15
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 15
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 15
- 241000208688 Eucommia Species 0.000 claims abstract description 15
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 15
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 15
- 241000258920 Chilopoda Species 0.000 claims abstract description 14
- 206010041591 Spinal osteoarthritis Diseases 0.000 claims abstract description 10
- 206010003246 arthritis Diseases 0.000 claims abstract description 5
- 208000036319 cervical spondylosis Diseases 0.000 claims abstract description 5
- 208000005801 spondylosis Diseases 0.000 claims abstract description 5
- 244000170916 Paeonia officinalis Species 0.000 claims abstract 3
- 238000000034 method Methods 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 17
- 239000000843 powder Substances 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 6
- 238000003958 fumigation Methods 0.000 claims description 6
- 239000000499 gel Substances 0.000 claims description 5
- 239000006210 lotion Substances 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 22
- 239000008280 blood Substances 0.000 abstract description 9
- 210000004369 blood Anatomy 0.000 abstract description 9
- 208000024891 symptom Diseases 0.000 abstract description 9
- 230000017531 blood circulation Effects 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 5
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 230000037081 physical activity Effects 0.000 abstract 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 25
- 208000006011 Stroke Diseases 0.000 description 21
- 241000736199 Paeonia Species 0.000 description 20
- 208000034783 hypoesthesia Diseases 0.000 description 16
- 206010008190 Cerebrovascular accident Diseases 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 201000010099 disease Diseases 0.000 description 12
- 210000003414 extremity Anatomy 0.000 description 10
- 235000011187 glycerol Nutrition 0.000 description 9
- 239000002552 dosage form Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 210000002683 foot Anatomy 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000003086 colorant Substances 0.000 description 6
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- -1 sucrose ester Chemical class 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229940107666 astragalus root Drugs 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 description 4
- 230000035807 sensation Effects 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 244000144730 Amygdalus persica Species 0.000 description 3
- 241000131329 Carabidae Species 0.000 description 3
- 241000903946 Clematidis Species 0.000 description 3
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 3
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010033425 Pain in extremity Diseases 0.000 description 3
- 244000197580 Poria cocos Species 0.000 description 3
- 235000008599 Poria cocos Nutrition 0.000 description 3
- 235000006040 Prunus persica var persica Nutrition 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 241001300193 Speranskia Species 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 239000013040 bath agent Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 229940010454 licorice Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 244000061520 Angelica archangelica Species 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 235000001287 Guettarda speciosa Nutrition 0.000 description 2
- 206010019468 Hemiplegia Diseases 0.000 description 2
- 208000004044 Hypesthesia Diseases 0.000 description 2
- 239000004368 Modified starch Substances 0.000 description 2
- 229920000715 Mucilage Polymers 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028836 Neck pain Diseases 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 201000007201 aphasia Diseases 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 210000003792 cranial nerve Anatomy 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000001341 hydroxy propyl starch Substances 0.000 description 2
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 210000004126 nerve fiber Anatomy 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000009023 proprioceptive sensation Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- DNISEZBAYYIQFB-PHDIDXHHSA-N (2r,3r)-2,3-diacetyloxybutanedioic acid Chemical compound CC(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(C)=O DNISEZBAYYIQFB-PHDIDXHHSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019452 Hemianopia Diseases 0.000 description 1
- 208000007460 Hemianopsia Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010050296 Intervertebral disc protrusion Diseases 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000031072 Somatosensory disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 235000010957 calcium stearoyl-2-lactylate Nutrition 0.000 description 1
- OEUVSBXAMBLPES-UHFFFAOYSA-L calcium stearoyl-2-lactylate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O.CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O OEUVSBXAMBLPES-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000012730 carminic acid Nutrition 0.000 description 1
- 239000004106 carminic acid Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- 229940106705 chlorophyll Drugs 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 229940080423 cochineal Drugs 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000011977 language disease Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229940057059 monascus purpureus Drugs 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000020470 nervous system symptom Diseases 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 description 1
- 229940075559 piperine Drugs 0.000 description 1
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 description 1
- 235000019100 piperine Nutrition 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000000272 proprioceptive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to the technical field of traditional Chinese medicines, in particular to a fumigation-washing traditional Chinese medicine composition for treating pain and application thereof, wherein the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 12-15 parts of Chinese herbaceous peony, 6-9 parts of liquorice, 10-15 parts of angelica dahurica, 15-20 parts of garden balsam stem, 15-20 parts of common clubmoss herb, 10-30 parts of myrrh, 10-15 parts of safflower, 15-25 parts of twotooth achyranthes root, 10-20 parts of doubleteeth pubescent angelica root, 10-20 parts of Chinese angelica, 10-15 parts of eucommia bark, 10-15 parts of clematis root, 1-3 parts of centipede, 12-15 parts of kudzu root and 9-12 parts of cassia twig. Its advantages are: the raw materials and the weight portion proportion thereof are optimized, the whole formula can be used for treating pains and numbness of neck, shoulder, waist and leg caused by lumbar spondylosis, cervical spondylosis, arthritis and the like and symptoms of physical activity difficulty caused by stroke, has stronger effects of promoting blood circulation to remove blood stasis, dispelling cold and removing dampness, and dredging collaterals and relieving pain, and has good curative effect and wide application prospect.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a fumigation-washing traditional Chinese medicine composition for treating pain and application thereof.
Background
At present, a plurality of patients with cervical and lumbar diseases have the following main symptoms: the pain of the cervical vertebra and the lumbar vertebra, the leg pain, the numbness of the hands and the feet, the inability to lift the arms and the inconvenient movement cause the serious reduction of the labor force, and directly influence the daily life of people.
In addition, the apoplexy patients are accompanied with the sequelae of numbness of hands and feet and inconvenient movement. Apoplexy (also known as acute cerebrovascular disease and cerebral apoplexy) is one of common diseases seriously harming human health and life, and has the characteristics of high morbidity, high disability rate and high mortality. The disease is rapid, has multiple symptoms, changes rapidly, and is similar to the characteristic of the good movement and the variability of wind, so the Chinese medicine is named as apoplexy and apoplexy. The age of onset also tends to be younger, and is therefore a significant condition threatening human life and quality of life. Acute cerebrovascular diseases in western medicine, such as cerebral infarction, cerebral hemorrhage, cerebral embolism, subarachnoid hemorrhage, and the like belong to the category of the diseases, and the causes of stroke are various and complex. Sequelae are often left in this disease. After a period of treatment, there are sequelae with different degrees, mainly hemiplegia, hemilateral limb disorder, numbness of limbs, hemianopsia, aphasia, etc. The root cause of the symptoms is that blood lesions such as high blood viscosity, high blood fat, high blood pressure, high blood sugar, platelet aggregation and the like and blood vessel lesions such as atherosclerotic plaque formation and the like appear in the cerebral blood vessels, and thrombus formed by the combined action of the two lesions blocks cerebral arteries, so that the blood flow of local brain is interrupted and cerebral tissues are subjected to ischemia and hypoxia necrosis. If the motor nervous system controlled by cranial nerves is affected, corresponding sequelae such as hemiplegia, limb disorders and the like can occur; if the central nervous system of the language controlled by the cranial nerves is affected, the corresponding nervous system symptoms such as language disorder and even aphasia can be caused. However, numbness of hands and feet is common after stroke, and the skin of the affected side of the patient, especially the end of the limb, such as the finger or toe, or the cheek of the hemiplegic side, has the feeling of ant-crawling, or has the feeling of needle-prick, or shows the slow response to stimulation. Numbness is often associated with changes in the weather, especially marked by rapid changes in the weather, damp and stuffy feeling, or before and after rain, cold weather, etc. Western medicine refers to pain, temperature and proprioception disorders in the lateral half of the patient. Nerve fibers conducting pain and warmth sensation pass from the skin receptors to nerve endings, pass into the posterior horn of the spinal cord, cross to the lateral side cables, go upward, pass through the capsular bag, and then reach the sensory center of the central nerve of cerebral cortex. The sensory center comprehensively analyzes the afferent stimulation to make a judgment whether the stimulation is hot, cold or painful. If the inner sac is damaged, the transmission of pain and temperature sensation of the opposite side is interrupted, so that pain and temperature sensation are disturbed. Proprioceptive receptors are stimulated to pass through the posterior cord of the spinal cord, up to the nucleus of the medullary wedge and the nucleus of the gracile, and then the nerve fibers exiting from these two nuclei cross over to the contralateral side, passing through the capsular bag, to the posterior midline. If the inner capsule is damaged, conduction to lateral involuntary proprioception is interrupted, and proprioceptive disorders such as loss of position sensation occur. For the sequelae of stroke, the treatment must be aggressive in time.
In view of the current situation, western medicine has no effective treatment method for sequelae caused by the above diseases, so that the invention provides a novel traditional Chinese medicine composition for treating pain in view of the defects of the prior art, and no report is found about the traditional Chinese medicine composition for treating pain by fumigation and washing and the application thereof at present.
Disclosure of Invention
The invention aims to provide a traditional Chinese medicine composition for treating pain and application thereof aiming at the defects of the prior art.
In order to achieve the purpose, the invention adopts the technical scheme that:
in a first aspect, the invention provides a traditional Chinese medicine composition for treating pain, which comprises the following raw material medicines in parts by weight: 12-15 parts of Chinese herbaceous peony, 6-9 parts of liquorice, 10-15 parts of angelica dahurica, 15-20 parts of garden balsam stem, 15-20 parts of common clubmoss herb, 10-30 parts of myrrh, 10-15 parts of safflower, 15-25 parts of twotooth achyranthes root, 10-20 parts of doubleteeth pubescent angelica root, 10-20 parts of Chinese angelica, 10-15 parts of eucommia bark, 10-15 parts of clematis root, 1-3 parts of centipede, 12-15 parts of kudzu root and 9-12 parts of cassia twig.
Preferably, the traditional Chinese medicine composition consists of the following raw material medicines in parts by weight: 15 parts of Chinese herbaceous peony, 8 parts of liquorice, 12 parts of angelica dahurica, 18 parts of garden balsam stem, 18 parts of common clubmoss herb, 20 parts of myrrh, 12 parts of safflower, 20 parts of twotooth achyranthes root, 15 parts of doubleteeth pubescent angelica root, 15 parts of Chinese angelica, 12 parts of eucommia bark, 12 parts of clematis root, 2 parts of centipede, 15 parts of kudzuvine root and 10 parts of cassia twig.
Further, the traditional Chinese medicine composition also comprises a pharmaceutically acceptable carrier.
Preferably, the dosage form of the traditional Chinese medicine composition is paste, powder, hip bath agent, fumigation agent, gel, spray, patch or cataplasm.
In a second aspect, the present invention provides a preparation method of the above-mentioned traditional Chinese medicine composition, comprising the step of weighing the raw materials according to the weight part ratio.
In a third aspect, the invention provides an application of the traditional Chinese medicine composition in preparing a medicine for treating pain.
Further, the invention provides application of the traditional Chinese medicine composition in preparing medicines for treating neck, shoulder, waist and leg pains and numbness caused by lumbar spondylosis, cervical spondylosis and arthritis.
Further, the invention provides application of the traditional Chinese medicine composition in preparing a medicine for treating numbness of hands and feet after stroke.
In a fourth aspect, the invention provides a fumigation-washing traditional Chinese medicine for treating pain, which is prepared from the traditional Chinese medicine composition.
Term(s) for
As used herein, an ingredient of the term "pharmaceutically acceptable" is one that is suitable for use in humans and/or animals without undue adverse side effects (such as toxicity, irritation, and allergic response), i.e., at a reasonable benefit/risk ratio.
As used herein, the term "pharmaceutically acceptable carrier" refers to a carrier for administration of a therapeutic agent, including various excipients and diluents and the like. The term refers to such pharmaceutical carriers: they are not essential active ingredients per se and are not unduly toxic after administration. Suitable carriers are well known to those of ordinary skill in the art. A thorough discussion of pharmaceutically acceptable excipients can be found in Remington's Pharmaceutical Sciences (mackpub.co., n.j.1991). Pharmaceutically acceptable carriers in the compositions may comprise liquids such as water, saline, glycerol and ethanol. In addition, auxiliary substances such as emulsifiers, fillers, binders, wetting agents, disintegrants, absorption enhancers, flavoring agents, colorants, cosolvents and the like may also be present in these carriers. The emulsifier is selected from acetylated monoglyceride, acetylated diglyceride, sucrose ester, sorbitol ester, soybean phospholipid, lauric monoglyceride, propylene glycol fatty acid ester, calcium stearoyl lactylate, diacetyl tartaric acid, glyceryl monostearate, modified soybean phospholipid, etc. Such as magnesium stearate, microcrystalline cellulose, lactose, milk sugar, high molecular weight polyethylene glycols, and the like. Such as starch, mannitol, silicic acid, dextrin, calcium hydrogen phosphate, cellulose, etc. Such as carboxymethyl cellulose, alginates, gelatin, polyvinyl pyrrolidone, gum arabic, starch slurry, hydroxypropyl starch, modified starch, pregelatinized starch, dextrin, microcrystalline cellulose, polyvinyl pyrrolidone mucilage, gelatin mucilage. Such as glycerin and the like. The disintegrating agent is agar, calcium carbonate, potato starch, tapioca starch, alginic acid, hydroxypropyl starch, modified starch, sodium carboxymethyl starch, microcrystalline cellulose, guar gum, xanthan gum, etc. The absorption enhancer is such as quaternary ammonium compound, effervescent agent, cyclodextrin, vitamin D and its derivatives, piperine, etc. The colorant may be a plant colorant, an animal colorant or a microbial colorant, such as beet red, turmeric, chlorophyll, shellac, cochineal, red yeast colorant, and the like. Such as beta-cyclodextrin, maltodextrin, tween, ethanol, span, sodium dodecyl sulfate, propylene glycol, polyethylene glycol, glycerol, etc. However, it will be appreciated by those skilled in the art that the pharmaceutically acceptable carriers useful in the present invention are not limited to the above-mentioned types.
As used herein, "parts by weight" can be any fixed weight expressed in milligrams, grams, or kilograms (e.g., 1mg, 1g, 2g, 5g, or 1kg, etc.). For example, a composition consisting of 1 part by weight of component a and 9 parts by weight of component b may be a composition consisting of 1g of component a +9 g of component b, or 10g of component a +90 g of component b. In the composition, the percentage content of a certain component is (parts by weight of the component/sum of parts by weight of all components) × 100%. Thus, in a composition consisting of 1 part by weight of component a and 9 parts by weight of component b, the content of component a is 10% and component b is 90%.
Dosage forms
The dosage form of the traditional Chinese medicine composition is not particularly limited, and can be any dosage form suitable for being taken by mammals; preferably, the dosage form may be selected from: ointment, powder, hip bath agent, fumigation agent, gel, spray, patch or cataplasm. From the standpoint of ease of preparation, administration or taking, the preferred Chinese medicinal composition is a lotion.
The composition of the present invention may be added with various conventional carriers or adjuvants required for the preparation of different dosage forms. Can be prepared into any common dosage form by conventional Chinese medicinal preparation method, such as unguent, powder, hip bath agent, fumigation lotion, gel, spray, patch or cataplasma.
Preparation method
After knowing the raw materials and their formulation used in the Chinese medicinal composition of the present invention, those skilled in the art can use various conventional methods to process the raw materials into drugs. Such processing includes, but is not limited to: pulverizing, extracting with water, extracting with organic solvent, etc. More specifically, the process comprises, for example, the steps of: weighing, pulverizing, decocting, etc.
The raw materials can be mixed and then the effective components are extracted by a proper method to prepare the traditional Chinese medicine composition; in addition, the effective components can also be extracted respectively (for example, the same or different extraction or processing methods are adopted respectively) and then combined to prepare the traditional Chinese medicine composition.
In addition, the technicians in the field can also directly adopt the effective parts of the raw material medicines for processing so as to prepare the traditional Chinese medicine composition. Furthermore, those skilled in the art can extract active ingredients from the raw materials, mix and process the active ingredients to prepare the traditional Chinese medicine composition.
Optionally, other pharmaceutically (or dietetically or nutraceutically) acceptable carriers can be added during the preparation process.
Use and method of use
The traditional Chinese medicine composition can be directly used for treating neck, shoulder, waist and leg pains, numbness and limb numbness after stroke caused by lumbar spondylosis, cervical spondylosis and arthritis.
The amount of the Chinese medicinal composition of the present invention to be used may vary depending on the mode of administration, the dosage form and the severity of the disease to be treated. For example, a single dose may be administered several times daily in divided doses, or the dose may be reduced proportionally as required by the condition being treated. Of course, the particular dosage will also take into account such factors as the mode of administration, the physical condition of the subject being administered, and the like, which are within the skill of the art.
The invention has the advantages that:
the raw materials and the weight part ratio thereof are optimized, the whole formula has the effects of promoting blood circulation to remove blood stasis, dispelling cold and removing dampness, and dredging collaterals and relieving pain, and the Chinese herbaceous peony and the liquorice in the formula have the effects of relieving spasm and pain as monarch drugs; clematis root, common clubmoss herb, garden balsam stem and doubleteeth pubescent angelica root are used as ministerial drugs, the clematis root, the common clubmoss herb, the garden balsam stem and the doubleteeth pubescent angelica root are used for dispelling wind and eliminating dampness, removing blood stasis and dredging Bi, relaxing tendons and activating collaterals, dredging collaterals and relieving pain, the myrrh is used for relaxing tendons and relieving pain, and activating blood circulation to remove; achyranthes and eucommia bark are used as adjuvant drugs for nourishing liver and kidney, strengthening tendons and bones and guiding drugs downwards; the angelica has the functions of promoting blood circulation and removing blood stasis, the angelica dahurica has the functions of expelling wind and removing cold, the cassia twig has the functions of warming and dredging channels and collaterals, and the kudzuvine root is supplemented to relieve various pains of neck and back. Wu Gong and Tian Long are used together to build the action of dredging collaterals and alleviating pain as guiding drugs. The traditional Chinese medicine has the effects of nourishing blood and activating blood circulation, removing dampness and dispelling cold, and dredging collaterals and relieving pain, has good curative effect, low cost and quick response on lumbar spondylosis, cervical spondylosis, arthritis, sequela of apoplexy and other diseases, and is safe and free of side effect when patients are fumigated and washed by the traditional Chinese medicine and are treated locally.
Detailed Description
The invention will be further illustrated with reference to specific embodiments. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. Furthermore, it should be understood that various changes and modifications can be made by those skilled in the art after reading the disclosure of the present invention, and equivalents fall within the scope of the appended claims.
EXAMPLE 1 Chinese medicinal composition 1
12 parts of Chinese herbaceous peony, 6 parts of liquorice, 10 parts of angelica dahurica, 15 parts of garden balsam stem, 15 parts of common clubmoss herb, 10 parts of myrrh, 10 parts of safflower, 15 parts of twotooth achyranthes root, 10 parts of doubleteeth pubescent angelica root, 10 parts of Chinese angelica, 10 parts of eucommia bark, 10 parts of clematis root, 1 part of centipede, 12 parts of kudzuvine root and 9 parts of cassia twig.
EXAMPLE 2 Chinese medicinal composition (II)
15 parts of Chinese herbaceous peony, 9 parts of liquorice, 15 parts of angelica dahurica, 20 parts of garden balsam stem, 20 parts of lycopodium clavatum, 30 parts of myrrh, 15 parts of safflower, 25 parts of twotooth achyranthes root, 20 parts of doubleteeth pubescent angelica root, 20 parts of Chinese angelica, 15 parts of eucommia bark, 15 parts of clematis root, 3 parts of centipede, 15 parts of kudzuvine root and 12 parts of cassia twig.
EXAMPLE 3 Chinese medicinal composition (III)
12 parts of Chinese herbaceous peony, 9 parts of liquorice, 10 parts of angelica dahurica, 20 parts of garden balsam stem, 15 parts of common clubmoss herb, 30 parts of myrrh, 10 parts of safflower, 25 parts of twotooth achyranthes root, 10 parts of doubleteeth pubescent angelica root, 20 parts of Chinese angelica, 10 parts of eucommia bark, 15 parts of clematis root, 1 part of centipede, 15 parts of kudzuvine root and 9 parts of cassia twig.
EXAMPLE 4 Chinese medicinal composition (IV)
15 parts of Chinese herbaceous peony, 6 parts of liquorice, 15 parts of angelica dahurica, 15 parts of garden balsam stem, 20 parts of common clubmoss herb, 10 parts of myrrh, 15 parts of safflower, 15 parts of twotooth achyranthes root, 20 parts of doubleteeth pubescent angelica root, 10 parts of Chinese angelica, 15 parts of eucommia bark, 10 parts of clematis root, 3 parts of centipede, 12 parts of kudzuvine root and 12 parts of cassia twig.
EXAMPLE 5 Chinese medicinal composition (V)
15 parts of Chinese herbaceous peony, 8 parts of liquorice, 12 parts of angelica dahurica, 18 parts of garden balsam stem, 18 parts of common clubmoss herb, 20 parts of myrrh, 12 parts of safflower, 20 parts of twotooth achyranthes root, 15 parts of doubleteeth pubescent angelica root, 15 parts of Chinese angelica, 12 parts of eucommia bark, 12 parts of clematis root, 2 parts of centipede, 15 parts of kudzuvine root and 10 parts of cassia twig.
EXAMPLE 6 Patch preparation
The preparation method comprises the following steps:
(1) taking the raw material medicines in the weight parts in any one of embodiments 1-5, crushing the raw material medicines, decocting for 3 times, adding 3 times of water for each time of decoction, filtering, combining filtrates, and concentrating the filtrate under reduced pressure to obtain an extract;
(2) stirring 3% glycerol and the extract uniformly, adding 3% dimethyl sulfoxide and 0.2% sorbic acid, and mixing with distilled water uniformly;
(3) filling into spray bottle, and sterilizing.
Example 7 cataplasm
The preparation method comprises the following steps:
(1) taking the raw material medicines in parts by weight in any one of embodiments 1-5, rolling the raw material medicines into coarse powder, heating and refluxing the coarse powder by using 70% ethanol water for 2 times, adding 10 times of ethanol water for the first time for 1 hour, adding 8 times of ethanol water for the second time for 1 hour, decompressing, recovering the ethanol water, and concentrating to obtain an extract;
(2) mixing 3% carbomer with the extract, and stirring to fully swell to form a mixed solution A; dispersing 20% polyvinyl alcohol (PVA) and 2% azone in 10% glycerin, stirring to form mixed solution B, mixing the mixed solution A and the mixed solution B uniformly, standing at 70 deg.C for 8 hr, swelling carbomer and polyvinyl alcohol (PVA), coating on non-woven fabric, and shearing. The size specification of the cataplasm obtained after shearing is 4cm × 6 cm.
EXAMPLE 8 gels
The preparation method comprises the following steps:
(1) taking the raw materials in any one of embodiments 1-5 in parts by weight, extracting the raw materials with 4 times of ethanol water solution, and recovering the ethanol water solution to obtain extract;
(2) mixing 3% sodium carboxymethylcellulose and 13% glycerol, adding water, stirring, adding triethanolamine, adjusting pH to 7, adding distilled water, packaging, and sterilizing.
Example 9 paste
The preparation method comprises the following steps:
taking the raw material medicines in any one of the embodiments 1-5 in parts by weight, carrying out ultrafine grinding on the raw material medicines into 200um ultrafine powder, adding 3 times of honey, stirring uniformly into paste, adding 10% of glycerol, mixing into paste, and subpackaging.
Example 10 lotion
The preparation method comprises the following steps:
(1) taking the raw material medicines in the weight parts in any one of embodiments 1-5, crushing the raw material medicines, decocting for 3 times, using 6 times of water for each time of decoction, filtering, combining filtrates, and concentrating the filtrate under reduced pressure to obtain an extract;
(2) uniformly stirring 3% of glycerol and the extract, adding 3% of dimethyl sulfoxide and 0.2% of sorbic acid, and uniformly mixing with distilled water to 2000 ml;
(3) filling into polyethylene bottle, and sterilizing.
EXAMPLE 11 Patch preparation
The preparation method comprises the following steps:
the preparation method comprises the following steps of taking the raw material medicines in parts by weight in the embodiment 1-5, carrying out ultrafine grinding on the raw material medicines, crushing the raw material medicines into ultrafine powder of 200um, adding glycerol, blending the ultrafine powder with vinegar into paste, coating the paste on non-woven fabrics, drying, applying a protective film (centrifugal paper), sterilizing and packaging.
EXAMPLE 12 clinical trial 1
1 data of
1.1 clinical data
96 patients with hand and foot numbness after stroke in Jinshan Hospital affiliated to the university of Fudan are selected for clinical diagnosis in 2015 5-2018 6, and are divided into four groups according to a random numerical table method, wherein the four groups are respectively an experimental group, a control group and a control group, and the patients in each group have no significant difference in age and disease course.
1.2 diagnostic criteria
The diagnosis standard of the apoplexy sequelae is made according to the Chinese medicine internal science which is the teaching material of the high traditional Chinese medicine academies in China. The cheeks have numbness, limb numbness and discomfort, hand and foot swelling, soreness and discomfort and limb conscious debilitation after the treatment of the apoplexy.
1.3 criteria for shedding
(1) Incomplete data will affect the final statistical data result.
(2) After inclusion, the false-selected person is found to be not in accordance with the inclusion standard, or the person in accordance with the exclusion standard.
2 method
2.1 methods of treatment
Experimental groups: the Chinese medicinal composition described in example 5 was administered.
Control group: administration of the Chinese medicinal composition: 10 parts of Chinese herbaceous peony, 5 parts of liquorice, 18 parts of angelica dahurica, 22 parts of garden balsam stem, 22 parts of common clubmoss herb, 8 parts of myrrh, 8 parts of safflower, 12 parts of twotooth achyranthes root, 22 parts of doubleteeth pubescent angelica root, 22 parts of Chinese angelica, 18 parts of eucommia bark, 8 parts of clematis root, 4 parts of centipede, 16 parts of kudzuvine root and 14 parts of cassia twig.
Control two groups: administration of the Chinese medicinal composition: 15 parts of Chinese herbaceous peony, 6 parts of liquorice, 20 parts of garden balsam stem, 20 parts of common clubmoss herb, 15 parts of myrrh, 15 parts of safflower, 12 parts of pubescent angelica root and 12 parts of clematis root.
Control three groups: administration of the Chinese medicinal composition: 15 parts of Chinese herbaceous peony, 6 parts of liquorice, 15 parts of radix stephaniae tetrandrae, 20 parts of garden balsam stem, 20 parts of lycopodium clavatum, 15 parts of myrrh, 15 parts of safflower, 15-25 parts of astragalus root, 12 parts of radix angelicae pubescentis, 15 parts of peach kernel, 15 parts of poria cocos, 12 parts of radix clematidis and 2 parts of ground beetle.
The traditional Chinese medicine compositions are prepared into fumigation lotion, a patient puts hands and feet into the liquid medicine to soak for 30 minutes, one dose is taken every day, the medicine is taken 2 times every day, 2 weeks are a treatment course, and evaluation is carried out after 2 treatment courses of the medicine is taken.
2.2 therapeutic efficacy assessment criteria
The medicine is formulated according to the curative effect standard of apoplexy sequelae of the national high-grade Chinese medicine academia textbook of internal science of traditional Chinese medicine.
And (3) healing: the symptoms of apoplexy sequelae such as numbness of affected limbs disappear.
The effect is shown: the symptoms of apoplexy sequelae such as numbness of affected limbs are obviously improved.
The method has the following advantages: the symptoms of apoplexy sequelae such as numbness of affected limbs are improved.
And (4) invalidation: the symptoms of apoplexy sequelae such as numbness of affected limbs are not improved.
3 results
The curative effect of each group is shown in table 1.
TABLE 1 curative effects of each group
4 conclusion
The results show that the experiment has the best curative effect on treating the apoplexy sequelae, is obviously superior to a control group, a control two group and a control three group, and has no toxic or side effect.
EXAMPLE 13 clinical trial (two)
1 data of
1.1 clinical data
206 patients with pain caused by cervical vertebra and lumbar vertebra of Jinshan hospital affiliated to the university of Fudan were selected for diagnosis 5-208-2015 and 6-month. Among them, there were 105 patients with pain caused by cervical vertebrae and 101 patients with pain caused by lumbar vertebrae. 105 patients with cervical pain were divided into 4 groups according to the random number table method, which were an experimental group, a control group, and the patients in each group had no significant difference in age and disease course. 101 patients with lumbar pain are divided into 4 groups according to a random numerical table method, namely an experimental group, a control two group and a control three group, and the patients in each group have no significant difference in age and disease course.
1.2 diagnostic criteria
Refer to the records in Chinese and Western diagnostics, lumbar disc herniation, cervical vertebra pain, arthralgia and rheumatic arthralgia.
1.3 criteria for shedding
(1) Incomplete data will affect the final statistical data result.
(2) After inclusion, the false-selected person is found to be not in accordance with the inclusion standard, or the person in accordance with the exclusion standard.
2 method
2.1 methods of treatment
2.1.1 cervical pain-causing patients:
experimental groups: the Chinese medicinal composition described in example 5 was administered.
Control group: administration of the Chinese medicinal composition: 10 parts of Chinese herbaceous peony, 5 parts of liquorice, 18 parts of angelica dahurica, 22 parts of garden balsam stem, 22 parts of common clubmoss herb, 8 parts of myrrh, 8 parts of safflower, 12 parts of twotooth achyranthes root, 22 parts of doubleteeth pubescent angelica root, 22 parts of Chinese angelica, 18 parts of eucommia bark, 8 parts of clematis root, 4 parts of centipede, 16 parts of kudzuvine root and 14 parts of cassia twig.
Control two groups: administration of the Chinese medicinal composition: 15 parts of Chinese herbaceous peony, 6 parts of liquorice, 20 parts of garden balsam stem, 20 parts of common clubmoss herb, 15 parts of myrrh, 15 parts of safflower, 12 parts of pubescent angelica root and 12 parts of clematis root.
Control three groups: administration of the Chinese medicinal composition: 15 parts of Chinese herbaceous peony, 6 parts of liquorice, 15 parts of radix stephaniae tetrandrae, 20 parts of garden balsam stem, 20 parts of lycopodium clavatum, 15 parts of myrrh, 15 parts of safflower, 15-25 parts of astragalus root, 12 parts of radix angelicae pubescentis, 15 parts of peach kernel, 15 parts of poria cocos, 12 parts of radix clematidis and 2 parts of ground beetle.
The traditional Chinese medicine compositions are prepared into paste, a patient takes the medicine for 2 times a day, 2 weeks are a treatment course, and the evaluation is carried out after the medicine is taken for 2 treatment courses.
2.1.2 lumbar pain-causing patients:
experimental groups: the Chinese medicinal composition described in example 5 was administered.
Control group: administration of the Chinese medicinal composition: 10 parts of Chinese herbaceous peony, 5 parts of liquorice, 18 parts of angelica dahurica, 22 parts of garden balsam stem, 22 parts of common clubmoss herb, 8 parts of myrrh, 8 parts of safflower, 12 parts of twotooth achyranthes root, 22 parts of doubleteeth pubescent angelica root, 22 parts of Chinese angelica, 18 parts of eucommia bark, 8 parts of clematis root, 4 parts of centipede, 16 parts of kudzuvine root and 14 parts of cassia twig.
Control two groups: administration of the Chinese medicinal composition: 15 parts of Chinese herbaceous peony, 6 parts of liquorice, 20 parts of garden balsam stem, 20 parts of common clubmoss herb, 15 parts of myrrh, 15 parts of safflower, 12 parts of pubescent angelica root and 12 parts of clematis root.
Control three groups: administration of the Chinese medicinal composition: 15 parts of Chinese herbaceous peony, 6 parts of liquorice, 15 parts of radix stephaniae tetrandrae, 20 parts of garden balsam stem, 20 parts of lycopodium clavatum, 15 parts of myrrh, 15 parts of safflower, 15-25 parts of astragalus root, 12 parts of radix angelicae pubescentis, 15 parts of peach kernel, 15 parts of poria cocos, 12 parts of radix clematidis and 2 parts of ground beetle.
The traditional Chinese medicine compositions are prepared into paste, a patient takes the medicine for 2 times a day, 2 weeks are a treatment course, and evaluation is carried out after the medicine is taken for 4 treatment courses.
2.2 methods of observation
Each patient was recorded with a history, signs, diagnosis, location and nature of pain and associated physical and physiological examinations.
2.3 therapeutic efficacy assessment criteria
And (3) healing: the symptoms disappear after treatment, and the clinical cure standard is reached;
the effect is shown: the physical signs of the illness are obviously improved after treatment;
the method has the following advantages: the physical signs of the disease are improved after treatment;
and (4) invalidation: there was no change before and after treatment.
3 results
3.1 curative effect of cervical vertebra pain-induced patients is shown in Table 2.
TABLE 2 curative effects on patients with pain due to lumbar vertebra
3.2 curative effect of cervical vertebra pain patients is shown in Table 3.
TABLE 3 curative effects on patients with pain caused by lumbar vertebra
4 conclusion
The results show that the experiment has the best curative effect on treating the apoplexy sequelae, is obviously superior to a control group, a control two group and a control three group, and has no toxic or side effect.
Example 14 animal experiments
This example demonstrates the analgesic efficacy of the compositions of the present invention in animal experiments.
1 materials and methods
Healthy male mice were taken 50 and randomized into 5 groups: an experimental group (example 5 traditional Chinese medicine composition), a control group (traditional Chinese medicine composition: 10 parts of peony, 5 parts of licorice, 18 parts of angelica dahurica, 22 parts of speranskia herb, 22 parts of lycopodium clavatum, 8 parts of myrrh, 8 parts of safflower, 12 parts of achyranthes root, 22 parts of pubescent angelica root, 22 parts of angelica, 18 parts of eucommia bark, 8 parts of clematis root, 4 parts of centipede, 16 parts of kudzu root and 14 parts of cassia twig), a control group (traditional Chinese medicine composition: 15 parts of peony, 6 parts of licorice, 20 parts of speranskia herb, 20 parts of lycopodium clavatum, 15 parts of myrrh, 15 parts of safflower, 15 parts of pubescent angelica root, 12 parts of clematis root), a control group (traditional Chinese medicine composition: 15 parts of peony, 6 parts of licorice, 15 parts of tetrandra root, 20 parts of speranskia herb, 20 parts of lycopodium clavatum, 15 parts of myrrh, 15 parts of safflower, 15-25 parts of astragalus root, 12 parts of, the administration is performed by intragastric administration, 1 time daily, and continuous administration for 3 days. After 1 hour of the last administration, each mouse was ip 0.9% glacial acetic acid solution 0.1mL 10g-1, and then the writhing reaction of the mouse was observed within 20min, and the writhing frequency of the mouse was recorded. The results are shown in Table 4.
2 results
TABLE 4 Effect of the groups on the writhing response of the mice to glacial acetic acid
Note: p <0.05 compared to saline group.
3 conclusion
The results show that the experimental group and each control group (from the control group to the control group) have obvious analgesic effect compared with the normal saline group, and the analgesic effect of the experimental group is obviously better than that of the control group to the control group.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and additions can be made without departing from the principle of the present invention, and these should also be considered as the protection scope of the present invention.
Claims (9)
1. The traditional Chinese medicine composition for treating pain is characterized by comprising the following raw material medicines in parts by weight: 12-15 parts of Chinese herbaceous peony, 6-9 parts of liquorice, 10-15 parts of angelica dahurica, 15-20 parts of garden balsam stem, 15-20 parts of common clubmoss herb, 10-30 parts of myrrh, 10-15 parts of safflower, 15-25 parts of twotooth achyranthes root, 10-20 parts of doubleteeth pubescent angelica root, 10-20 parts of Chinese angelica, 10-15 parts of eucommia bark, 10-15 parts of clematis root, 1-3 parts of centipede, 12-15 parts of kudzu root and 9-12 parts of cassia twig.
2. The traditional Chinese medicine composition according to claim 1, which is prepared from the following raw materials in parts by weight: 15 parts of Chinese herbaceous peony, 8 parts of liquorice, 12 parts of angelica dahurica, 18 parts of garden balsam stem, 18 parts of common clubmoss herb, 20 parts of myrrh, 12 parts of safflower, 20 parts of twotooth achyranthes root, 15 parts of doubleteeth pubescent angelica root, 15 parts of Chinese angelica, 12 parts of eucommia bark, 12 parts of clematis root, 2 parts of centipede, 15 parts of kudzuvine root and 10 parts of cassia twig.
3. The Chinese medicinal composition of any one of claims 1-2, wherein the Chinese medicinal composition further comprises a pharmaceutically acceptable carrier.
4. The Chinese medicinal composition according to any one of claims 1 to 2, wherein the Chinese medicinal composition is in the form of a paste, powder, hip bath, lotion, gel, spray, patch or cataplasm.
5. The method for preparing a Chinese medicinal composition according to any one of claims 1 to 4, comprising the step of weighing the raw material medicaments in part by weight.
6. Use of a Chinese medicinal composition according to any one of claims 1 to 4 in the manufacture of a medicament for the treatment of pain.
7. The use of the Chinese medicinal composition of any one of claims 1-4 in the preparation of a medicament for treating pain and numbness in the neck, shoulder, waist and legs caused by lumbar spondylosis, cervical spondylosis and arthritis.
8. Use of the Chinese medicinal composition of any one of claims 1-4 in the preparation of a medicament for the treatment of deadlimb following stroke.
9. A fumigation and washing traditional Chinese medicine for treating pain, which is characterized in that the medicine is prepared from the traditional Chinese medicine composition of any one of claims 1 to 2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110162397.4A CN112675226A (en) | 2021-02-05 | 2021-02-05 | Fumigation-washing traditional Chinese medicine composition for treating pain and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110162397.4A CN112675226A (en) | 2021-02-05 | 2021-02-05 | Fumigation-washing traditional Chinese medicine composition for treating pain and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112675226A true CN112675226A (en) | 2021-04-20 |
Family
ID=75457881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110162397.4A Pending CN112675226A (en) | 2021-02-05 | 2021-02-05 | Fumigation-washing traditional Chinese medicine composition for treating pain and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112675226A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104306942A (en) * | 2014-10-30 | 2015-01-28 | 崔银方 | Medicine for auxiliary treatment on cervical spondylosis |
| CN104383039A (en) * | 2014-12-06 | 2015-03-04 | 唐云峰 | Traditional Chinese medicine composition for treating sciatica |
| CN111700936A (en) * | 2020-07-13 | 2020-09-25 | 付军 | Thermotherapy medicinal liquid for treating osteopathy and preparation method of thermotherapy brick |
-
2021
- 2021-02-05 CN CN202110162397.4A patent/CN112675226A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104306942A (en) * | 2014-10-30 | 2015-01-28 | 崔银方 | Medicine for auxiliary treatment on cervical spondylosis |
| CN104383039A (en) * | 2014-12-06 | 2015-03-04 | 唐云峰 | Traditional Chinese medicine composition for treating sciatica |
| CN111700936A (en) * | 2020-07-13 | 2020-09-25 | 付军 | Thermotherapy medicinal liquid for treating osteopathy and preparation method of thermotherapy brick |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102552613A (en) | Externally applied Chinese medicinal paste for treating lumbar disc diseases | |
| CN101757313B (en) | Liquid medicine | |
| CN104274546B (en) | A kind of external medicine composition, traditional Chinese medicine for outer use and its preparation method and application | |
| CN107095982A (en) | A kind of Tong,-a topical application of drug agent and preparation method thereof | |
| CN101361819A (en) | Novel external traditional Chinese medicine liniment for relaxing muscles and tendons and relieving pain | |
| CN102145057A (en) | Antispasmodic traditional Chinese medicine composition and preparation method thereof | |
| CN109432269A (en) | A kind of Chinese medicine composition and preparation method, purposes | |
| CN111729015A (en) | A drug for adjuvant treatment of knee osteoarthritis | |
| CN112675226A (en) | Fumigation-washing traditional Chinese medicine composition for treating pain and application thereof | |
| CN109224032A (en) | A kind of Chinese medicine composition and preparation method thereof for treating cervical spondylosis | |
| CN109498775A (en) | It is a kind of to treat cervical vertebra, the oral traditional Chinese medicine composition of lumbar pain and preparation method | |
| CN104825563B (en) | A kind of Chinese medicine preparation treating cervical spondylosis and preparation method thereof | |
| CN100372551C (en) | Chinese medicine for treating hyperosteogeny | |
| CN101518579B (en) | Pressure stabilizing deoppilant and preparation process | |
| CN113967231A (en) | External traditional Chinese medicine composition for treating wind-cold-dampness arthralgia, and preparation method and application thereof | |
| CN112807363A (en) | Traditional Chinese medicine composition for warming and activating meridians, massage cream and preparation method and application thereof | |
| CN112121086A (en) | A Chinese medicinal tincture for transdermal therapy and its preparation method | |
| CN112755134B (en) | Plaster for treating hyperosteogeny and preparation method thereof | |
| CN104971286A (en) | Traditional Chinese medicine composition for treating shoulder, waist and leg discomfort | |
| CN114984116B (en) | Essential oil composition with pain relieving effect and application thereof | |
| CN114028483B (en) | Pharmaceutical composition and preparation for treating chronic soft tissue injury | |
| CN111375040A (en) | Pain-relieving traditional Chinese medicine nano-emulsion dispersion liquid, preparation method and application | |
| CN103860676A (en) | Traditional Chinese medicine external preparation for treating lumbar muscle strain and preparation method thereof | |
| CN101897822B (en) | Traditional Chinese medicinal preparation for treating hyperosteogeny and prolapse of intervertebral discs and preparation method thereof | |
| CN108837056A (en) | For treating the nano traditional Chinese medicine liposome aqueogel and preparation method of skeletal joint disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210420 |